Evidence map›Paper›PMID 42017263›Full record

ArticleLab on a chip2026

Cell therapy manufacturing at full clinical scale: enhancing the quality CAR-T cell therapy starting materials through massively parallel automated microfluidic cell sorting.

Alison M Skelley, Yasna Behmardi, Luke F Peterson, David W Inglis, Mabel Shehada, Laurissa Ouaguia, Khushroo Gandhi, Roberto Campos-González, Tony Ward

Abstract read
In one paragraph

Article in Lab on a chip, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alison M SkelleyCurate Biosciences, USA.ORCID 0009-0000-2994-6201
Yasna BehmardiCurate Biosciences, USA.
Luke F PetersonCurate Biosciences, USA.
David W InglisSchool of Engineering, Macquarie University, Sydney, NSW 2109, Australia.ORCID 0000-0001-8239-5568
Mabel ShehadaCurate Biosciences, USA.
Laurissa OuaguiaCurate Biosciences, USA.
Khushroo GandhiCurate Biosciences, USA.
Roberto Campos-GonzálezCurate Biosciences, USA.
Tony WardCurate Biosciences, USA.

Funding

Microfluidic CAR-T Cell Processing DeviceR42CA228616 · NCI · GPB SCIENTIFIC, INC. · PI CIVIN, CURT I, STURM, JAMES C · 2018 to 2020
$2.1M
NCI NIH HHS R42 CA228616
6 · The paper itself

Abstract

Autologous CAR-T cell therapy has demonstrated remarkable clinical efficacy in hematologic malignancies, yet its broader application remains limited by complex, labor-intensive cell therapy manufacturing and inconsistent product quality. We describe a novel microfluidic cell separation platform based on deterministic lateral displacement (DLD), integrated into a fully automated, closed-system instrument (Curate system).

Indexed as

Cell- and Tissue-Based TherapyCell SeparationLab-On-A-Chip DevicesMicrofluidic Analytical TechniquesAutomationCytokinesFlow CytometryHumansT-LymphocytesCytokines

Identifiers

PMID42017263
PMCPMC13100876

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.